{
    "id": "dbpedia_7734_2",
    "rank": 67,
    "data": {
        "url": "https://www.ifpma.org/events/24th-ifpma-assembly/",
        "read_more_link": "",
        "language": "en",
        "title": "24th IFPMA Assembly",
        "top_image": "https://www.ifpma.org/wp-content/uploads/2023/04/ifpma-logo-social-preview.png",
        "meta_img": "https://www.ifpma.org/wp-content/uploads/2023/04/ifpma-logo-social-preview.png",
        "images": [
            "https://www.ifpma.org/wp-content/uploads/2024/04/vaccinesforlife-initiative-header-1080x680-1-255x161.webp",
            "https://www.ifpma.org/wp-content/uploads/2023/12/campaign-img-initiative-alwaysinnovating-255x161@2x-255x161.webp",
            "https://www.ifpma.org/wp-content/uploads/2023/12/GHP-Relaunch-SocialBanners-Menu-255x161.webp",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Carol-Adelman.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Jorge-Amigo.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Paul-Anthony.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Richard-Bagger.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Alessandro-Banchi.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Richard-Barker.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Thomas-Barker.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Richard-Bergstrom.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Peter-Brabeck-Letmathe.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Craig-Brammer.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_John-Breaux.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Shing-Chang.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Richard-Clark.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Thomas-Cueni-190x190.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Vicki-Ehrich.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Alicia-Greenidge.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Fred-Hassan.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Karen-Ignagni.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Michel-Kazatchkine.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Hannah-Kettler.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_William-Kingsmill.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Elaine-Leavenworth.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_John-Lechleiter.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Klaus-Leisinger.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Bernard-Lemoine.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Trent-Lott.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Mark-McClellan.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Haruo-Naito.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Richard-Nduhuura.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Gilles-Pajot.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Rosanna-Peeling.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Swati-Piramal.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Geralyn-Ritter.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Jeffrey-Sachs.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Julian-Schweitzer.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Robert-Sebbag.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Bennett-Shapiro.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Mae-Shieh.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Billy-Tauzin.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Russell-Williams.jpg",
            "https://www.ifpma.org/wp-content/uploads/2023/01/i2023_Weibo-Zhang.jpg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2008-11-18T13:46:26+00:00",
        "summary": "",
        "meta_description": "Improving Global Health Outcomes through Innovation and Better Access",
        "meta_lang": "en",
        "meta_favicon": "https://www.ifpma.org/wp-content/uploads/2022/10/cropped-favicon-1-32x32.png",
        "meta_site_name": "IFPMA",
        "canonical_link": "https://www.ifpma.org/events/24th-ifpma-assembly/",
        "text": "Date\n\n18 - 19 November 2008\n\nTime\n\n08:00 to 17:00\n\nLocation\n\nRitz Carlton Pentagon City\n\nAttendance\n\nThis event has now passed. To browse our upcoming events click here.\n\nImproving Global Health Outcomes through Innovation and Better Access\n\nProgram\n\nTuesday, 18 November 2008\n\nAll panels are in Salon I & II (Ballroom level)\n\nLunches are in Salon III (Ballroom level)\n\nThe Assembly Reception & Dinner will take place at the Embassy of Italy\n\n8:00 AM\n\nRegistration Desk Opens\n\n12:30 AM - 2:00 PM\n\nOpening Lunch\n\nWelcome Remarks\n\nMr. Fred Hassan, Chairman & CEO, Schering-Plough; President, IFPMA\n\nProf. Jeffrey Sachs, Director, the Earth Institute\n\nMr. Richard T. Clark, Chairman & CEO, Merck & Co., Inc; President, PhRMA\n\nMme Alicia D. Greenidge, Director General, IFPMA\n\n2:00 PM - 2:45 PM\n\nPanel 1: “How can innovation advance health care?”\n\nThomas Cueni, Secretary General, Interpharma, Switzerland (Moderator)\n\nMr. Craig Brammer, Institute for the Study of Health, University of Cincinatti\n\nDr. Ben Shapiro, Partner – PureTech Ventures and Board Chair, DNDi North America\n\nMr. Haruo Naito, Vice President, IFPMA & President and CEO, Eisai\n\n2:45 PM - 3:00 PM\n\nBreak\n\n3:00 PM - 4:15 PM\n\nPanel 2: “What is needed to achieve the millennium development goals in health?”\n\nBernard Lemoine, Executive President, Les Entreprises du Médicament (LEEM), France\n\n(Moderator)\n\nH.E. Prof. Peter Anyang’ Nyong’o, Minister of Medical Services, Kenya\n\nH.E. Dr. Richard Nduhuura, Minister of State for Health, Uganda\n\nMr. William Kingsmill, Acting Director, Policy & Research, Department for International\n\nDevelopment, UK\n\nDr. Alessandro Banchi, Chairman, Boehringer Ingelheim\n\n4:15 PM - 4:30 PM\n\nBreak\n\n4:30 PM - 5:30 PM\n\nPanel 3: “How are emerging countries promoting a climate for innovation to foster economic\n\ndevelopment and improved health?”\n\nMs. Vicki Ehrich, Chief Operating Officer, PIASA, South Africa (Moderator)\n\nMr. Zhang Weibo, Director, Pharmaceutical & Biological Invention Review, SIPO, P.R.\n\nChina\n\nMr. Jorge Amigo, Director General, Mexican Institute of Industrial Property\n\nDr. Swati Piramal, Director, Strategic Alliances, Piramal Healthcare Ltd, India\n\nMs. Geralyn Ritter, Vice President, Global Public Policy, Merck & Co., Inc.\n\n6:30 PM - 10:00 PM\n\nReception & Dinner (Italian Embassy)\n\nOpening Remarks\n\nMr. Billy Tauzin, President & CEO, PhRMA\n\nKeynote Speaker\n\nDr. Mark B. McClellan, Director, Engelberg Center for Health Care Reform, USA\n\n7:30 AM - 8:45 AM\n\nBreakfast Briefing: “Global Health Progress Initiative” (Ballroom Salon III)\n\nDr. Paul Anthony, Executive Director, Global Health Progress\n\n9:00 AM - 9:30 AM\n\nKeynote Speakers\n\nH.E. Mme Chantal Compaoré, First Lady for Burkina Faso, Honorary President of\n\nSynergies Africaines\n\nProf. Michel Kazatchkine, Executive Director, Global Fund to Fight AIDS, TB and Malaria\n\n9:30 AM - 10:30 AM\n\nPanel 4: “How to help build capacity and improve access to safe and quality health care in\n\ndeveloping countries?”\n\nDr. Robert Sebbag, Vice-President, Access to Medicines, sanofi-aventis (Moderator)\n\nMr. Julian Schweitzer, Director of Health, The World Bank\n\nProf. Klaus M. Leisinger, President & Executive Director, Novartis Foundation for\n\nSustainable Development\n\nMs. Elaine Leavenworth, Vice President Government Affairs, Abbott Laboratories\n\n10:30 AM - 10:45 AM\n\nBriefing: “IFPMA – bolstering sustainable industry responses in Geneva”\n\nMme Alicia D. Greenidge, Director General, IFPMA\n\n10:45 AM - 11:00 AM\n\nBreak\n\n11:00 AM - 12:00 PM\n\nPanel 5: “Can the public and private sectors complement each other in providing effective,\n\nsustainable and transparent health care in the United States?”\n\nMr. Russell Williams, President, Canada’s Research-Based Pharmaceutical Companies,\n\nCanada (Moderator)\n\nMr. Thomas R. Barker, Acting General Counsel, Department of Health and Human\n\nServices\n\nMs. Karen Ignagni, President and CEO, American Health Insurance Plans\n\nMr. John Lechleiter, President & CEO, Lilly\n\n12:00 PM - 1:30 PM\n\nLuncheon & Keynote Speakers\n\nSenators John Breaux and Trent Lott, The Breaux Lott Leadership Group\n\n1:30 PM - 2:00 PM\n\nIFPMA President’s Address\n\nMr. Fred Hassan, Chairman & CEO, Schering-Plough; President IFPMA\n\n2:00 PM - 2:30 PM\n\nKeynote Speaker\n\nMr. Peter Brabeck-Letmathe, Chairman of the Board of Directors, Nestlé S.A\n\n2:30 PM - 3:15 PM\n\nPanel 6: “What are industry corporate social responsibility actions delivering today?”\n\nMr. Richard Bergstrom, Director General, Läkemedelsindustrieföreningen (LIF), Sweden\n\n(Moderator)\n\nDr. Hannah Kettler, Global Health Policy and Finance, The Bill and Melinda Gates\n\nFoundation\n\nDr. Carol C. Adelman, Director, Center for Global Prosperity, Hudson Institute, USA\n\nMr. Rich Bagger, Senior Vice President, Worldwide Public Affairs and Policy, Pfizer\n\n3:15 PM - 3:30 PM\n\nBreak\n\n3:30 PM - 4:30 PM\n\nPanel 7: “Can R&D partnerships address all unmet developing world health needs?”\n\nDr. Richard Barker, Director General, Association of the British Pharmaceutical Industry,\n\nUK (Moderator)\n\nDr. Rosanna Peeling, Coordinator, Neglected Priority Needs Research, TDR\n\nDr. Shing Chang, R&D Director, Drugs for Neglected Diseases Initiative\n\nMs. Mae Shieh, Head, Business Development & Partnerships, Novartis Vaccines Institute\n\nfor Global Health\n\n4:30 PM - 5:00 PM\n\nGlobal Pharmaceutical Market Update\n\nMr. Gilles Pajot, Executive Vice President and Chief Operating Officer, IMS Health Inc.\n\nSpeakers\n\nCarol Adelman Director of the Center for Global Prosperity, Hudson Institute\n\nDr. Carol Adelman, director of the Center for Global Prosperity at the Hudson\n\nInstitute, publishes the annual Index of Global Philanthropy, a guide to private\n\nphilanthropy and remittance flows abroad. She served as an Assistant Administrator\n\nat USAID in charge of foreign aid to Asia, the Middle East and Eastern Europe. Dr.\n\nAdelman was vice chair of the H.E.L.P Commission, a bipartisan commission to\n\nreform foreign aid, and is vice chair of an advisory committee to USAID. She writes\n\non global philanthropy and economic development in The New York Times, Foreign\n\nAffairs, Wall Street Journal, International Herald Tribune, and technical journals. Dr.\n\nAdelman is a vice chairman of the Atlantic Council and member of the Council on\n\nForeign Relations. She holds a doctorate in Public Health from Johns Hopkins\n\nUniversity, a Masters in Foreign Service from Georgetown University, and a B.A. from the University of Colorado.\n\nJorge Amigo Head of the Mexican delegation for intellectual property matters\n\nJorge Amigo has a BA in economics from Anahuac University and an MA from the\n\nUniversity of the Americas. Between 1970 and 1984, he was Relations Manager at\n\nthe Banco de Comercio, Marketing Manager for Jeffrey Manufacturera Mexicana, a\n\nmaterial handling manufacturer and General Manager of Menite Metal de México, an\n\niron foundry. He entered public service in 1984, with positions including Director of\n\nEconomic Evaluation at the Ministry of Commerce (1986); Technical Secretary of the\n\nNational Foreign Investment Commission (1989); Director General of Foreign\n\nInvestment (1990-1992). In 1993, he became Director General of Technological\n\nDevelopment of the Ministry of Commerce and in 1994, Mr. Amigo was appointed by\n\nPresident Ernesto Zedillo to his current position as Director General of the Mexican\n\nInstitute of Industrial Property. Mr. Amigo headed the Mexican delegation for the\n\nnegotiation of the Investment Chapter of the North American Free Trade Agreement\n\n(NAFTA). Since 1993, he has been Head of the Mexican delegation for intellectual\n\nproperty matters, in negotiations of Free Trade Agreements and in fora such as\n\nWIPO, FTAA and APEC. In all of the latter bodies, he has been elected or appointed\n\nto leadership positions. He is a member of the National College of Economists,\n\nteaches at his alma mater and has published extensively.\n\nPaul Anthony Chief Medical Officer, Pharmaceutical Research and Manufacturers of America (PhRMA)\n\nPaul Antony, MD, MPH is Chief Medical Officer at the Pharmaceutical Research and\n\nManufacturers of America (PhRMA), and is its principal advocate on all health care\n\nand medical policy issues. Dr. Antony is board-certified by the American Board of\n\nPreventive Medicine and joined PhRMA after serving in the U.S. Navy as Flight\n\nSurgeon and Senior Medical Officer for the Marine One Presidential Helicopter\n\nSquadron. He received his Doctor of Medicine and Master of Public Health degrees\n\nfrom the George Washington University Medical Center and now serves on its faculty\n\nin the department of Microbiology, Immunology, and Tropical Medicine. Prior to\n\nattending medical school, he earned an MBA from Harvard Business School, and\n\nreceived a Bachelor of Science degree in biomedical engineering from Johns Hopkins\n\nUniversity. Dr. Antony was a 1993-1994 White House Fellow serving in the Executive\n\nOffice of the President. He continues to treat patients as a reservist in the U.S. Navy\n\nand is a member of the American Medical Association and the American College of\n\nPreventive Medicine.\n\nRichard Bagger Head of Worldwide Public Affairs and Policy, Pfizer\n\nRich Bagger heads Worldwide Public Affairs and Policy for Pfizer, with responsibility\n\nfor public policy, government relations, international public affairs, corporate\n\nresponsibility, philanthropy and stakeholder advocacy. Prior to joining Pfizer in 1993,\n\nhe was Assistant General Counsel of Blue Cross and Blue Shield of New Jersey, and\n\npracticed law with McCarter and English. He was Chairman of the Appropriations\n\nCommittee and Majority Conference Leader in the New Jersey General Assembly. In\n\n2001, he was elected to the New Jersey Senate and served there until 2003. He is\n\nChairman of the Board of Trustees of the Healthcare Institute of New Jersey, and\n\nserves on the Board of Trustees of the United States Chamber of Commerce, the New\n\nJersey Performing Arts Center, the United Hospital Fund, Kean University and the\n\nWestfield United Way. He received an A.B. degree from Princeton University’s\n\nWoodrow Wilson School of Public and International Affairs and a J.D. degree from\n\nRutgers University Law School.\n\nAlessandro Banchi Member of the Board of Managing Directors, Boehringer Ingelheim\n\nDr. Banchi joined the Boehringer Ingelheim Italian organisation in the marketing and\n\nsales department in 1973. He worked for BI USA Corporation 1985 to1986 and the\n\nreturned to Italy, where he was appointed Managing Director of Boehringer Ingelheim\n\nItalia S.p.A in 1991. From 1992 he headed Boehringer Ingelheim Group in Italy as\n\nCountry Manager. Since January 1st, 2000 he has been a Member of the Board of\n\nManaging Directors of Boehringer Ingelheim, responsible for the Corporate Board\n\nDivision Pharma Marketing and Sales. As of January 1st, 2004 he became Chairman\n\nof the Board of Managing Directors. At the moment, Dr. Banchi is Vice-President of\n\nthe Council of IFPMA (International Federation of Pharmaceutical Manufacturers &\n\nAssociations ) and Member of the Board of EFPIA (European Federation of\n\nPharmaceutical Industries and Associations).\n\nRichard Barker Director General, the Association of the British Pharmaceutical Industry (ABPI)\n\nRichard is Director General of the Association of the British Pharmaceutical Industry,\n\nand a board member of EFPIA and council member of IFPMA. His priorities include\n\nboosting the UK and Europe as a global leader in pharmaceutical innovation,\n\nstrengthening the partnership between the industry and the Health Service,\n\nincreasing patient engagement and access to new medicines in the UK and globally,\n\nand ensuring that the industry’s external image reflects its major contribution to\n\nhealth and economic prosperity. He is Chairman of Stem Cells for Safer Medicines, a\n\npublic-private partnership developing stem cell technology for predicting the safety\n\nprofile of new medicines. He is a Board member of Datapharm Communications, a\n\ncompany bringing on-line medicines information to UK prescribers and patients. He is\n\nalso a member of the Ministerial Strategy Group for the industry, the NHS National\n\nLeadership Network and Stakeholder Forum, and Vice-Chairman of the UK Clinical\n\nResearch Consortium and of its Advisory Board on Connecting for Health. He is a\n\nstakeholder in the TB Alliance, which is developing new medicines for this\n\ndevastating condition.\n\nThomas Barker Acting General Counsel, US Department of Health and Human Services (HHS)\n\nThomas R. Barker is Acting General Counsel of the US Department of Health and\n\nHuman Services (HHS), overseeing all legal matters affecting HHS and its agencies,\n\nincluding the Centers for Medicare & Medicaid Services (CMS); the Food and Drug\n\nAdministration (FDA); the Office of the National Coordinator for Health Information\n\nTechnology, (ONC); and the Office of Civil Rights (OCR). Mr. Barker supervises a\n\nstaff of 450 attorneys and is responsible for the legal accuracy of all regulations\n\nissued by the Department and its agencies, and the conduct of all litigation to which\n\nthe Department is a party. Prior to assuming this role in May 2008, he was senior\n\npolicy advisor to the Secretary of HHS from 2005, Deputy General Counsel of HHS,\n\nresponsible for the CMS Division of OGC (2003-05) and Health Policy Counselor to\n\nthe Administrator of CMS (2001-03). From 1992-2001, Mr. Barker was a health policy\n\nanalyst and regulatory counsel for the Massachusetts Hospital Association. Mr.\n\nBarker is also an assistant professor of health law at the George Washington\n\nUniversity School of Public Health and Health Services in Washington, D.C. and a\n\nmember of the adjunct faculty of Suffolk University School of Law. He teaches\n\ncourses in Medicare and Medicaid law; tax law issues in health care; and introductory\n\nhealth law.\n\nRichard Bergstrom Director-General, LIF, the Swedish Association of the Pharmaceutical Industry\n\nRichard Bergstrom has an MScPharm from the University of Uppsala, Sweden. Until\n\n1992 he worked at the Medical Products Agency as Assistant Head of Registration.\n\nHe then worked for nine years ins Switzerland in regulatory affairs at Roche and\n\nNovartis. Currently, he is Director-General of LIF, the Swedish Association of the\n\nPharmaceutical Industry, Member of the Board of the European association EFPIA,\n\nand of the Council of the IFPMA. Mr Bergstrom is particularly involved in policies\n\nrelating to health technology assessment (HTA) and marketing codes. In the latter\n\narea he serves as chair of the IFPMA Code Compliance Network and chair of the\n\nEFPIA Code Steering Committee. In Sweden, he has been appointed by the\n\nGovernment to the Board of the Karolinska Institute. He has also been appointed\n\nadvisor to the World Health Organization in Geneva in the project for good\n\ngovernance in the health sector.\n\nPeter Brabeck-Letmathe Chairman, Nestlé S.A.\n\nBorn in Austria in 1944, Peter Brabeck-Letmathe completed his studies in Economics\n\nat the University of World Trade in Vienna and joined Nestlé Austria in 1968. His\n\ninternational career included almost 10 years in Chile. In 1981, he was appointed\n\nManaging Director of Nestlé Ecuador, in 1983, President and Managing Director of\n\nNestlé Venezuela. In 1987, he transferred to the international headquarters as Senior\n\nVice President responsible for the Culinary Products Division. In 1992 he was\n\nappointed Executive Vice President of Nestlé S.A. with worldwide leadership of\n\nstrategic business groups while simultaneously being in charge of Marketing,\n\nCommunications and Public Affairs. At the Ordinary General Meeting of Shareholders\n\nin 1997, he was elected Member of the Board of Directors and CEO of Nestlé S.A. In\n\n2001 he was elected Vice-Chairman of the Board, in 2005 Chairman of the Board\n\nand in 2008, he handed over the office of CEO and is now Chairman of Nestlé S.A.\n\nCraig Brammer Senior Research Associate, Institute for the Study of Health at the University of Cincinnati Academic Health Center\n\nCraig Brammer is Senior Research Associate with the Institute for the Study of\n\nHealth at the University of Cincinnati Academic Health Center, where he is currently\n\nDirector of Aligning Forces for Quality: The Regional Market Project (Cincinnati, OH),\n\none of 14 in the United States to align incentives, engage consumers and measure\n\nperformance for improving healthcare quality. Mr. Brammer recently served as\n\nPrincipal Investigator in studies to assist the Ohio Department of Jobs and Family\n\nServices in the design of Ohio Medicaid’s pay-for-performance (P4P) strategy,\n\nincluding evaluating metrics for appropriateness in Medicaid, surveying health plans\n\non their P4P approach, and working with physicians and other stakeholders on P4P\n\ndesign characteristics. He previously authored studies for the Institute of Medicine,\n\nNational Rural Health Association and others on performance measurement and\n\npractice redesign. Mr. Brammer is Co-Director of the Humana/University of Cincinnati\n\nPhysician Leadership Program; Co-Principal Investigator for multiple grants and\n\nprojects on medical education in healthcare improvement at the University of\n\nCincinnati; and leads the Institute’s Health Policy Forum seminar series.\n\nJohn Breaux Former Senator, US\n\nSenator John Breaux’s career in Congress began when he was elected to the House\n\nof Representatives in 1972 at the age of 28, for the 7th District of Louisiana, and was\n\nelected to fill Senator Russell Long’s seat in 1986. Senator Breaux was a recognized\n\nbipartisan leader and in 1993 was elected Democratic Deputy Minority Whip, a\n\nposition he held until his retirement. A senior member of the Finance Committee,\n\nSenator Breaux served as the Chairman of the Subcommittee on Social Security and\n\nFamily Policy. He also held positions on the Subcommittees on Health Care and on\n\nTaxation and IRS Oversight. On the Finance Committee, he helped pass welfare\n\nreform and health insurance reform bills, reduce capital gains tax and provide tax\n\nrelief for college education expenses. As Chairman of the Special Committee on\n\nAging, Senator Breaux helped protect and strengthen Social Security, Medicare, and\n\nother programs. In 1998 he was selected to chair the National Bipartisan Commission\n\non the Future of Medicare. Also in 1998, Senator Breaux co-chaired the National\n\nCommission on Retirement Policy, which produced legislation to help reform Social\n\nSecurity. He served as Co-Chair of the Oil and Gas Caucus and helped write the\n\n2005 Energy Bill. Senator Breaux was active in advancing legislation to promote\n\ndomestic oil and gas production, and was a Co-Sponsor of the Marginal Well\n\nPreservation Act, a tax-incentive program to encourage oil production from marginal\n\noil wells. He was also a principal author of the Outer Continental Shelf Land Act.\n\nSenator Breaux was a founder of the Centrist Coalition of Senate Democrats and\n\nRepublicans and served as Chairman of the Democratic Leadership Council. In 2005\n\nPresident George W. Bush appointed Senator Beaux as the Co-Chair of the\n\nPresident’s Advisory Panel on Federal Tax Reform. Upon retirement from the Senate\n\nin 2005, Senator Breaux joined Patton Boggs as Senior Counsel. In 2008, Senator\n\nBreaux joined forces with former Senator Trent Lott to form the Breaux Lott\n\nLeadership Group, providing advice on public policy matters, especially health care\n\nand energy.\n\nShing Chang R&D Director, DNDi\n\nDr. Shing Chang joined DNDi as R&D Director in October 2007. In this position he is\n\nresponsible for building DNDi’s project portfolio and advance the discovery and\n\ndevelopment of new treatments for neglected diseases. Prior to joining DNDi, Dr.\n\nChang was Senior Vice President, Drug Discovery and Chief Scientific Officer at\n\nICOS Corporation. From 1991 to 2006, Dr. Chang held various management\n\npositions at Abbott Laboratories in diagnostics and pharmaceutical research,\n\nincluding 7 years as Divisional Vice President, Infectious Disease Research. In 1978,\n\nhe joined Cetus Corporation as one of its first molecular biologists. Dr. Chang held\n\nvarious positions at Cetus including Vice President, Preclinical and Development, a\n\nposition he held until 1991. Dr. Chang completed post doctoral fellowships at the\n\nUniversity of Wisconsin and Stanford University. He received his Ph.D. in molecular\n\nbiology and biochemistry from the University of California, Santa Barbara and his\n\nBachelor of Science in biology from Fu-Jen Catholic University in Chinese Taipei.\n\nRichard Clark President and CEO, Merck & Co., Inc.\n\nRichard T. Clark has been President and CEO of Merck & Co., Inc. since May 2005,\n\nand Chairman of the Board since April 2007. Mr. Clark joined Merck in 1972 as a\n\nQuality Control Inspector, and progressed through a series of increasingly\n\nresponsible roles in production, new products planning, industrial engineering and\n\nmanagement engineering, becoming Vice President, Materials Management and\n\nManagement Engineering in 1991. In 1993, Mr. Clark was appointed Vice President,\n\nProcurement and Materials Management. He became Vice President of North\n\nAmerican Operations for the Merck Manufacturing Division in 1994 and Senior Vice\n\nPresident in 1996. In 1997, he was appointed Senior Vice President of Quality and\n\nCommercial Affairs. Later that year, Mr. Clark joined the Merck-Medco Managed\n\nCare subsidiary as Executive Vice President and Chief Operating Officer. He later\n\nserved as Chairman, President and Chief Executive Officer of the newly named\n\nMedco Health Solutions, overseeing plans to prepare that organization to become a\n\npublicly traded company. He returned to the Merck Manufacturing Division as\n\nPresident in June 2003. In April 2008, Mr. Clark was elected board chairman of the\n\nPharmaceutical Research and Manufacturers of America (PhRMA), which represents\n\nthe country’s leading pharmaceutical research and biotechnology companies. Mr.\n\nClark earned his bachelor’s degree in Liberal Arts from Washington & Jefferson\n\nCollege, and his M.B.A. from American University. He served as a Lieutenant in the\n\nU.S. Army from 1970 to 1972 before joining Merck.\n\nChantal Compaoré First Lady of Burkina Faso\n\nChantal Compaoré, First Lady of Burkina Faso, is the wife of Blaise Compaoré who\n\nbecame President in 1987. She is active in Burkina Faso and Africa, leading\n\nphilanthropic activities to help women and children, and to fight HIV/AIDS. Mme\n\nCompaoré created the Suka Foundation in 1999 to help children, notably thought the\n\nSOS Children village in Ziniaré, in which CFA 500 million has been invested to date.\n\nSuka also helps vaccinate against polio and tetanus, and works to increase tolerance\n\nfor maladjusted children. Mme Compaoré has also been a driving force behind the\n\nbuilding of schools. Mme Compaoré is honorary president of Synergies Africaines, an\n\nassociation of African First Ladies which works to diminish the impact of HIV/AIDS\n\nwithin the continent. Synergies helps patients to live with their disease, and\n\nencourages them to use experiences to help educate others about its dangers. The\n\nSuka Foundation also helps with prevention of mother-to-child transmission of\n\nHIV/AIDS, and also helps to treat children with AIDS. Mme Compaoré is also active\n\non behalf of the Biya Foundation, which works to increase HIV testing. Mme\n\nCompaoré also strives to improve the lives of women. In 2005, she created a\n\nwomen’s house in Balé for vulnerable women, and she works to improve girls’\n\nliteracy, to motivate parents to educate their daughters and to encourage better\n\ntreatment of women. She also helps the Karité organization to provide assistance to\n\nunderprivileged women.\n\nThomas\n\nThomas Cueni Secretary General, Interpharma\n\nThomas B. Cueni is Secretary General of Interpharma, the association of the Swiss\n\npharmaceutical research companies. Mr. Cueni is a member of the Board of the\n\nEuropean Federation of the Pharmaceutical Industries’ Associations (EFPIA) and is\n\non various committees of the IFPMA. Mr. Cueni also serves on the Swiss Federal\n\nMedicines Committee, an advisory body to the Swiss Government. Prior joining\n\nInterpharma, Mr. Cueni worked as a journalist for two Swiss newspapers. In 1983,\n\nMr. Cueni joined the Swiss Foreign Service as a career diplomat with postings in\n\nVienna at the Swiss Mission to the United Nations, the International Atomic Energy\n\nAgency, and the United Nations Industrial Development Organisation, and in Paris,\n\nwhere he was a member of the Swiss Delegation to the OECD. Mr. Cueni has a\n\ndegree in economics (University of Basle) and a post-graduate degree in politics\n\n(M.Sc.) from the London School of Economics.\n\nVicki Ehrich Chief Operating Officer, Pharmaceutical Industry Association of South Africa (PIASA)\n\nVicki Ehrich is Chief Operating Officer of the Pharmaceutical Industry Association of\n\nSouth Africa (PIASA), representing multinational and local pharmaceutical\n\ncompanies. As COO of the former Pharmaceutical Manufacturers’ Association\n\nsince February 2004, Vicki helped form PIASA, which is a member IFPMA. Before\n\nthat, Vicki was Director, Corporate Affairs, at GlaxoSmithKline South Africa,\n\nresponsible for government affairs, external communications, internal\n\ncommunications, community relations and corporate social investment. During her\n\n15 years with GSK, Vicki held various positions including Marketing Director,\n\nDirector of Business Development and, more recently, Director of Corporate Affairs.\n\nVicki also spent 2 years with GSK Corporate Communications in the UK, as\n\nDirector, External Affairs HIV/AIDS, responsible for the Positive Action Programme,\n\nsupporting communities affected by HIV/AIDS, and was extensively involved in\n\naccess to medicines issues. Vicki has worked for four pharmaceutical companies,\n\nranging from multinationals to South African generic companies. Vicki has a BCom\n\n(Hons) degree from the former University of Port Elizabeth now Nelson Mandela\n\nMetropolitan University.\n\nAlicia Greenidge Director General, IFPMA\n\nAlicia Greenidge was appointed Director General of the IFPMA in June 2008. She has\n\nmore than 15 years experience in bilateral and multilateral negotiations with\n\ngovernments in the Americas, Africa, Asia, Pacific, Middle East, and Europe, working\n\nlargely for the Office of the United States Trade Representative in Washington and in\n\nGeneva. She served as Assistant Deputy Chief of Mission and Senior Counsel in\n\nGeneva for the last 8 years. She contributed to many settlements before the World\n\nTrade Organization, notably the Public Health Declaration and subsequent agreements\n\nconcerning local pharmaceutical manufacturing in developing countries. She also\n\nworked on issues on the relationship between the Trade Related Intellectual Property\n\nRights Agreement (TRIPS), and the Convention on Biodiversity and agreements on\n\nLeast Developed Country matters under TRIPS. Since 1998, she also has interacted\n\nwith, and advised on issues before, other inter-governmental organizations, such as\n\nWHO (including infant formula, health personnel, IGWG issues and the IGM on virus\n\nsharing and access to vaccines), UNAIDS, WIPO, UNCTAD and others. In addition,\n\nshe has engaged constructively with several non-governmental organizations in\n\nGeneva. She has a Juris Doctorate from Boston College, a Master’s degree in Public\n\nInternational Law & International Development Economics from the American\n\nUniversity, and a Bachelor’s degree in International Relations and Sociology from C.W.\n\nPost College/LIU.\n\nFred Hassan Chairman of the board and Chief Executive Officer, Schering-Plough Corporation\n\nFred Hassan is chairman of the board and chief executive officer of Schering-Plough\n\nCorporation. He was elected President of the IFPMA in October 2006. Prior to joining\n\nSchering-Plough in April 2003 and assuming his current position, Mr. Hassan was\n\nchairman and chief executive officer of Pharmacia Corporation. He joined the former\n\nPharmacia & Upjohn in May 1997 as chief executive officer and was elected to the\n\nBoard of Directors. In February 2001, Mr. Hassan was named chairman of the Board\n\nof Pharmacia. Previously, Mr. Hassan was executive vice president of Wyeth,\n\nformerly known as American Home Products, with responsibility for its\n\npharmaceutical and medical products business. He was elected to Wyeth’s Board of\n\nDirectors in 1995. Mr. Hassan also spent 17 years with Sandoz Pharmaceuticals\n\n(now Novartis) and headed its U.S. pharmaceuticals business. He is the past\n\nchairman of the Board of Directors of the Pharmaceutical Research and\n\nManufacturers of America (PhRMA) and is the immediate past chairman of the\n\nHealthCare Institute of New Jersey.\n\nKaren Ignagni President and Chief Executive Officer, America’s Health Insurance Plans (AHIP)\n\nKaren Ignagni is President and Chief Executive Officer of America’s Health Insurance\n\nPlans (AHIP), representing members that provide health care, long-term care, dental\n\nand disability benefits to more than 200 million Americans. AHIP was formed in 2003\n\nafter a merger of the Health Insurance Association of America and the American\n\nAssociation of Health Plans. Ms Ignagni led the latter body since 1993. Ranked by\n\nthe Hill Newspaper as one of Washington’s most effective lobbyists, Ms. Ignagni\n\nregularly testifies before Congress and has published numerous articles. Prior to\n\njoining AAHP, Ms. Ignagni directed the AFL-CIO’s Department of Employee Benefits.\n\nIn the 1980s, she was a Professional Staff Member on the U.S. Senate Labor and\n\nHuman Resources Committee, preceded by work at the Committee for National\n\nHealth Insurance and the U.S. Department of Health and Human Services.\n\nMichel Kazatchkine Executive Director, Global Fund to fight AIDS, tuberculosis and malaria\n\nProfessor Michel D. Kazatchkine became Executive Director of the Global Fund to\n\nfight AIDS, tuberculosis and malaria in 2007. He has spent the past 25 years fighting\n\nAIDS as a leading physician, researcher, administrator, advocate, policy maker, and\n\ndiplomat. He studied at Necker-Enfants-Malades, Paris, the Pasteur Institute, St\n\nMary’s hospital, London and Harvard Medical School, and was Professor of\n\nImmunology at Université René Descartes and Head of the Immunology Unit of the\n\nGeorges Pompidou Hospital in Paris. He has authored or coauthored of over 500\n\narticles, on subjects such as auto-immunity, immuno-intervention and pathogenesis\n\nof HIV/AIDS. Dr. Kazatchkine was Director of the National Agency for Research on\n\nAIDS (ANRS) in France (1998-2005), French Ambassador for HIV/AIDS and\n\ncommunicable diseases (2005-2007), Vice-Chair of the Board of the Global Fund\n\n(2005-2006), first Chair of the Technical Review Panel of the Global Fund (2002-\n\n2005), Chair of the WHO’s Strategic and Technical Advisory Committee on HIV/AIDS\n\n(2004-2007), and a member of the WHO’s Scientific and Technical Advisory Group\n\non tuberculosis (2004-2007). While recognizing the enormous challenges of tackling\n\nHIV/AIDS, tuberculosis and malaria globally, Dr. Kazatchkine believes that the\n\nprogress made in recent years, particularly through programs supported by the\n\nGlobal Fund, presents enormous opportunities. He also emphasizes the importance\n\nof partnerships.\n\nHannah Kettler Economist and Senior Program Officer, Bill and Melinda Gates Foundation\n\nHannah Kettler is an economist and senior program officer on the Global Health\n\nAdvocacy team at the Bill and Melinda Gates Foundation. She is responsible for\n\nprojects to secure adequate financing and a supportive policy environment for global\n\nhealth product innovation and introduction. Much of her work is focused on designing\n\nof financial incentives and business models to encourage greater private sector\n\ncompany engagement. Prior to joining the Gates Foundation in 2003, Hannah led a\n\ntwo year Rockefeller Foundation funded project titled “Biotechnology and Global\n\nHealth” at the Institute for Global Health at the University of California San Francisco.\n\nThe work motivated BIO and the Bill and Melinda Gates Foundation to establish\n\nBioVentures for Global Health in 2004. Between 1998 and 2001 Hannah worked as\n\nthe Senior Industrial Economist for the Office of Health Economics (OHE) in London.\n\nHannah has a PhD in Industrial Economics from the University of Notre Dame.\n\nWilliam Kingsmill Acting Director, UK government’s Department for International Development (DFID)\n\nWilliam Kingsmill is currently Acting Director of the Policy and Research Division of\n\nthe UK government’s Department for International Development (DFID) based in\n\nLondon. Prior to this he held the post of Head of DFID’s Growth and Investment\n\nGroup and was Head of DFID’s office in Nigeria. Previous posts he has held in DFID\n\nhave included Head of Private Sector Policy Department and Head of Economic\n\nPolicy and Research Department. He has worked for DFID in the Caribbean and in\n\nEast Africa. He has also worked for the European Commission, working on the\n\ndesign and implementation of the Euro-Mediterranean Partnership, and for the\n\nGovernment of Botswana as an Economic Adviser.\n\nElaine Leavenworth Vice President, Government Affairs, Abbott\n\nElaine Leavenworth serves as Vice President, Government Affairs for Abbott, a\n\nglobal, broad-based health care company. She is responsible for International,\n\nFederal and State efforts to identify, assess and address regulatory, administrative\n\nand legislative proposals and actions that will impact the company and patients.\n\nLeavenworth joined Abbott in 1991 and has held various commercial management\n\npositions in Abbott’s Nutrition, International and Health Systems divisions. She was\n\nelected to her position as a corporate officer in July 1999. Prior to joining Abbott,\n\nLeavenworth was a principal with the consulting firm Louden & Company, where her\n\nwork focused on marketing and strategy assignments for health care providers,\n\nsuppliers, investors and associations. While at Louden & Company, she also\n\npublished numerous articles and several books on the health care market.\n\nLeavenworth also held marketing positions at G.D. Searle & Co. and American\n\nHospital Supply Corporation.\n\nJohn Lechleiter President and Chief Executive Officer, Eli Lilly and Company\n\nJohn Lechleiter, Ph.D., was named president and chief executive officer of Eli Lilly\n\nand Company in April 2008. John earned a bachelor of science degree in chemistry\n\nat Xavier University (Cincinnati) and master’s and doctoral degree in organic\n\nchemistry at Harvard University. He joined Lilly in 1979 as a senior organic chemist\n\nand subsequently held a number of management positions in Lilly Research\n\nLaboratories. He is a member of the American Chemical Society. In 2004, he was\n\nappointed to the Visiting Committee of Harvard Business School and to the Health\n\nPolicy and Management Executive Council of the Harvard School of Public Health.\n\nHe also serves as a member of the Board of Trustees of Xavier University. In\n\naddition, he is a distinguished advisor of The Children’s Museum of Indianapolis, a\n\nmember of the board of directors and executive committee of Fairbanks Institute, and\n\na member of the United Way of Central Indiana board of directors. He also serves on\n\nthe board of Indianapolis Downtown, Inc.\n\nKlaus Leisinger Chief Executive Officer and President of the Board of Trustees, Novartis Foundation for Sustainable Development\n\nKlaus Leisinger is Chief Executive Officer and President of the Board of Trustees of\n\nthe Novartis Foundation for Sustainable Development, which has consultative status\n\nwith the Social and Economic Council of the United Nations. In addition, he is\n\nProfessor of Sociology at the University of Basel where he teaches business ethics,\n\nCorporate Social Responsibility, as well as Human Rights and Business. Leisinger\n\nserved as guest professor at several Swiss and German universities, as well as at\n\nthe University of Notre Dame, the MIT Sloan School of Management (Cambridge),\n\nand Harvard University. He is a member of the European Academy of Sciences and\n\nArts. Leisinger has held advisory positions in the United Nations Global Compact, the\n\nUnited Nations Development Program (UNDP), the World Bank (CGIAR), Asian\n\nDevelopment Bank as well as Economic Commission for Latin America (ECLA).\n\nAmong others, he chairs of the Board of Trustees of the German Network Business\n\nEthics. Leisinger served as “Special Advisor of the United Nations Secretary General\n\nfor the UN Global Compact” for Kofi Annan, 2005-07.\n\nBernard Lemoine Executive Vice President, Les Entreprises du Médicament (LEEM)\n\nSince 1998, Bernard Lemoine has been Executive Vice President of the French\n\npharmaceutical industry association, which is now known as Les Entreprises du\n\nMédicament (LEEM). From 1979 to 1988, he was International Affairs Director, then\n\nDeputy Director General of Fournier Laboratories. Bernard Lemoine is a member of\n\nthe Council for the Future of Health Insurance, of the French Health Care System\n\nAccounts Commission, of the Council for Transparency in Health Insurance\n\nStatistics, and a board member of the European Federation of Pharmaceutical\n\nIndustries and Associations and IFPMA. Dr. Lemoine has been instrumental in\n\ncreating the public-private architecture for pharmaceutical regulation which has made\n\nof France the leading market for medicines in Europe. He has a Doctorate in Law\n\nand a PhD in Management.\n\nTrent Lott Former Senator, US\n\nIn 2007, US Senator Trent Lott left the US Congress where he worked for the people\n\nof Mississippi for 35 years. As the House Republican Whip in 1981, he forged the\n\nbipartisan alliance that enacted President Ronald Reagan’s economic recovery\n\nprogram and his national security initiatives. Elected to the Senate in 1988, he\n\nopposed the tax increase forced on President Bush in 1990. Becoming Senate\n\nMajority Leader in 1996, with House Speaker Newt Gingrich, he enacted his historic\n\nwelfare reform bill of 1996. The next year, Lott, Gingrich and congressional Budget\n\nCommittee chairmen John Kasich and Pete Domenici together produced an historic\n\nbudget and tax cut agreement that limited some federal spending. As the Republican\n\nLeader during the first two years of President George W. Bush’s administration,\n\nSenator Lott led the fight for passage of the President’s tax cut package, the\n\nPresident’s landmark education reform bill, the largest increase in defense spending\n\nsince the Cold War, the most significant trade legislation in a decade, and the\n\nresolution supporting the President on military action in Iraq. During the Senate’s\n\nlame duck session of November 2002, Senator Lott, drawing on his experience as a\n\nlegislative negotiator, reached the compromises that created the Department of\n\nHomeland Security. In 2006, Senator Lott was elected Senate Republican Whip for\n\nthe second time in his career. He is the only member of Congress to hold this\n\nposition in both the House and Senate. After his retirement from the United States\n\nSenate, Senator Lott founded the Breaux Lott Leadership Group with former Senator\n\nJohn Breaux of Louisiana, a partnership offering strategic advice, consulting and\n\nlobbying.\n\nMark McClellan Director, Engelberg Center, Brookings Institution\n\nDr. Mark B. McClellan became Director of the Engelberg Center for Healthcare\n\nReform at the Brookings Institution in 2007 and also holds the Leonard D. Schaeffer\n\nChair in Health Policy Studies. He was administrator for the Centers for Medicare and\n\nMedicaid Services (2004-2006) and commissioner of the Food and Drug\n\nAdministration (2002-2004). He served on the President’s Council of Economic\n\nAdvisers and was senior director for health care policy at the White House (2001–\n\n2002). Dr. McClellan was associate professor of economics and associate professor\n\nof medicine (with tenure) at Stanford University, directing its Health Outcomes\n\nResearch program and was associate editor of the Journal of Health Economics, and\n\nco-principal investigator of the Health and Retirement Study (HRS). He is a Member\n\nof the Institute of Medicine of the National Academy of Sciences, a Research\n\nAssociate of the National Bureau of Economic Research, and a Visiting Scholar at\n\nthe American Enterprise Institute. A graduate of the University of Texas at Austin, Dr.\n\nMcClellan earned his M.P.A. from Harvard’s Kennedy School of Government, his\n\nM.D. from the Harvard-MIT Division of Health Sciences and Technology, and his\n\nPh.D. in economics from MIT. He completed residency training in internal medicine at\n\nBrigham and Women’s Hospital, Boston, has been board-certified in Internal\n\nMedicine and has been a practicing internist.\n\nHaruo Naito President and CEO of Eisai Co., Ltd.\n\nMr. Haruo Naito has been President and CEO of Eisai Co., Ltd. of Japan since 1988\n\nand instituted the company’s new strategic orientation focusing on active participation\n\nin numerous facets of human health care delivery systems. Under his leadership,\n\nEisai has established a global strategic research network, consisting of research\n\ncenters in the USA, Europe and Asia. In addition, Eisai now has business activities in\n\nsome forty countries throughout the world. Mr. Naito currently serves on\n\nNorthwestern University’s Kellogg Advisory Board and Duke University’s Fuqua\n\nBoard of Visitors. He also serves as Vice President of the International\n\nPharmaceutical Manufacturers & Associations (IFPMA). In April 1999, he was\n\nawarded an honorary CBE by the United Kingdom in recognition of his long-standing\n\nefforts in strengthening UK – Japan relations.\n\nRichard Nduhuura Minister of State for Health, Uganda\n\nDr. Richard Nduhuura is a Veterinary Doctor and has been Minister of State for\n\nHealth, General Duties, in the Government of Uganda since June 2006. Prior to his\n\ncurrent appointment, he served as Minister of State for Industry and Technology\n\n(2001–2003), Minister of State for Trade (2003–2005) and Minister of State for Local\n\nGovernment (2005–2006). Since 2001, he has represented the Igara East\n\nConstitituency in the Bushenyi District of South Western Uganda as its Member of\n\nParliament. He has served both as Secretary General and Chairman of the Uganda\n\nNational Farmers Association. During his professional career, he has practiced as a\n\nVeterinary Officer in both public and private sectors and has lectured at the\n\nVeterinary Training Institute in Entebbe, Uganda. His current task is to ensure the\n\nfunctionality of general hospitals and effective collaboration with institutions related to\n\nthe health sector. He is also tasked with setting up of a National Insurance Scheme\n\nto ensure affordable and equitable access to health in the country.\n\nPeter Nyong’o Minister for Medical Services, Kenya\n\nProf. Peter Nyong’o is currently the Minister for Medical Services in the Government\n\nof Kenya, having previously served as Minister for Planning and National\n\nDevelopment. He was first elected to the Kenyan Parliament in 1992 and has been a\n\nMember of Parliament since then, first as an opposition back-bencher (1992 – 2002)\n\nand then as Minister. He is a Political Scientist with a Ph. D. (1977) from the\n\nUniversity of Chicago and has published extensively on the political economy of\n\ndevelopment, state and social classes, democracy and democratization in Africa. His\n\nlatest book, “A Leap Into the Future”, is an analysis of the political economy of\n\ndevelopment in Kenya and prospects for “catching up” with the developed world.\n\nGilles Pajot Chief Operating Officer, IMS Health\n\nGilles V.J. Pajot is Chief Operating Officer of IMS Health responsible for business\n\noperations and leveraging IMS’ capabilities, offerings and services worldwide. Named\n\nto this position in January 2007, he previously served as Executive Vice President\n\nand President, Global Business Management for one year. Prior to that, he was\n\nExecutive Vice President and President, Europe, Middle East and Africa. Pajot joined\n\nthe company in December 1997 as Vice Chairman of IMS and President of IMS,\n\nEurope. Previously, he was Senior Vice President of Pharmacia & Upjohn’s Europe,\n\nMiddle East and Africa Region. He also served on the merger team that formed\n\nPharmacia & Upjohn in 1995. In more than 23 years at Pharmacia AB, Pajot held\n\nvarious positions running its subsidiaries in France from 1979 to 1990, and serving as\n\nCEO and President of Global Pharmacia Biosystems AB 1990 to 1991. A French\n\nnational, Pajot holds a Master’s in Biochemistry and Chemistry from Rennes\n\nUniversity and a BSc. degree from Nantes University.\n\nRosanna Peeling Tropical Diseases (TDR), World Health Organization\n\nDr. Peeling is the Research Coordinator for the UNICEF/UNDP/World Bank/WHO\n\nSpecial Programme on Research and Training in Tropical Diseases (TDR), based in\n\nthe World Health Organization in Geneva, Switzerland. Trained as a medical\n\nmicrobiologist, Dr. Peeling had been in charge of Diagnostics R&D in TDR and the\n\nCanadian National Laboratory for Sexually Transmitted Diseases before assuming\n\nher current position. She is the author of over 100 peer-reviewed publications,\n\nauthoritative reviews and book chapters. She has a strong interest in ethical issues\n\nassociated with conducting research in developing countries and was appointed the\n\nChair of the WHO Research Ethics Review Committee 2004-6. She was the recipient\n\nof a YM-YWCA Women of Distinction Award, a 5NR Award for Canadian Leaders of\n\nSustainable Development. Her research was featured in a Discovery Channel\n\ndocumentary on Chlamydia infection and infertility, and in Fighting Syphilis, a\n\ndocumentary in the highly acclaimed BBC Kill or Cure series.\n\nSwati\n\nSwati Piramal Director, Piramal Healthcare Ltd and Vice Chairperson, Piramal Life Sciences Ltd\n\nDr Swati Piramal, Director, Piramal Healthcare Ltd, is responsible for the company’s\n\nR&D, Strategic Alliances, Communications, Knowledge Management & Public Policy.\n\nAs Vice Chairperson, Piramal Life Sciences Ltd, which has a pipeline of 14 NCE’s in\n\ndiabetes, cancer, infectious disease and inflammation, she oversees Strategic\n\nResearch Planning, Discovery Research and Clinical Research. Dr Piramal has\n\nauthored papers on Drugs Price Control; Biotechnology Regulation on Biosimilars;\n\nData Protection Laws & Patentability and co-authored books on nutrition &\n\nphilosophy, and is the recipient of the Chevalier de l’Ordre National du Merite (2006),\n\nBMA Management Woman Achiever (2004-05), Science & Technology National\n\nLeadership (2006), Rajiv Gandhi Award for Outstanding Woman Achiever (2007) and\n\nDistinguished Scientist Oration, Ministry of Science & Technology (2008); She is a\n\nstrong proponent of Intellectual Property. Piramal holds Board positions across the\n\nPiramal Group & in other key organizations, universities and government bodies.\n\nGeralyn Ritter Vice President, Global Public Policy, at Merck & Co., Inc.\n\nGeralyn S. Ritter is Vice President, Global Public Policy, at Merck & Co., Inc.,\n\nresponsible for public policy, government affairs and corporate responsibility matters.\n\nShe was previously Senior Vice President for International Affairs at the\n\nPharmaceutical Research and Manufacturers of America (PhRMA) and before that\n\nAssistant General Counsel for international issues. Prior to joining PhRMA, Ms. Ritter\n\nserved as Trade Counsel at the Washington law firm of Covington & Burling, where\n\nshe represented clients on international trade and intellectual property matters. Ms.\n\nRitter also served for three years as Associate General Counsel for intellectual\n\nproperty matters at the Office of the U.S. Trade Representative in the Executive\n\nOffice of the President. She represented the USA in the first IP case it filed under the\n\nWTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) at\n\nthe WTO in Geneva, as well as in the first such case filed against the USA. Ms. Ritter\n\nhas MA in International Studies from the School of Advanced International Studies\n\n(SAIS) at Johns Hopkins University, a law degree from the Stanford University\n\nSchool of Law, and a BA in economics and political science from Duke University.\n\nJeffrey Sachs Director of The Earth Institute, Quetelet Professor of Sustainable Development, and Professor of Health Policy and Management at Columbia University\n\nJeffrey D. Sachs is the Director of The Earth Institute, Quetelet Professor of\n\nSustainable Development, and Professor of Health Policy and Management at\n\nColumbia University. He is also Special Advisor to UN Secretary-General Ban Kimoon\n\non the Millennium Development Goals. From 2002 to 2006, he was Director of\n\nthe UN Millennium Project. Sachs is President and Co-Founder of Millennium\n\nPromise Alliance, a nonprofit organization aimed at ending extreme global poverty.\n\nProfessor Sachs is in the forefront of addressing the challenges of economic\n\ndevelopment, poverty alleviation, and globalization, promoting policies to help\n\neveryone benefit from expanding economic opportunities and wellbeing while\n\nensuring environmental sustainability. He has been a senior advisor to governments\n\nworldwide, and has worked with international agencies, businesses, and\n\nhumanitarian organizations to forge new strategies for sustainable development. As\n\nDirector of the Earth Institute, Prof. Sachs leads a large-scale effort to harness\n\nsciences including climatology, hydrology, engineering, economics, geography, and\n\npublic health to ensure sustainable development. Sachs is author of hundreds of\n\narticles and many books, including the bestsellers Common Wealth and The End of\n\nPoverty. Sachs is a member of the Institute of Medicine and is a Research Associate\n\nof the National Bureau of Economic Research. He has twice been named among the\n\n100 most influential leaders in the world by Time Magazine. He was awarded the\n\nPadma Bhushan, a high civilian honor bestowed by the Indian Government, in 2007.\n\nA native of Detroit, Michigan, Sachs received his B.A., M.A., and Ph.D. degrees at\n\nHarvard University.\n\nJulian Schweitzer Director, Health Nutrition and Population, World Bank\n\nJulian Schweitzer is the Director, Health Nutrition and Population in the Human\n\nDevelopment Network of the World Bank and was previously Director of the Human\n\nDevelopment Sector in the South Asia Region of the World Bank, responsible for the\n\nBank’s operations in health, nutrition, population, education and social protection.\n\nDuring his career in the Bank, he has also worked in the Middle East and North\n\nAfrica, Latin America and the transition economies of Europe, managing operations\n\nin health, education, and social protection. He has also worked as the Operations\n\nDirector in the Bank’s East Asia and Pacific region and as the Bank’s Country\n\nDirector based in Russia. In South Asia, he developed sectoral approaches to\n\nmobilize external financing. He strengthened the Bank’s regional HIV/AIDS\n\nengagement with clients and external partners, and its advisory and financial roles.\n\nHe holds a Ph.D. from the University of London and has authored numerous articles\n\nand essays on economic and human development.\n\nRobert Sebbag Vice President for Access to Medicines, sanofi-aventis\n\nDr Robert Sebbag is currently Vice President for Access to Medicines at sanofiaventis.\n\nIn this role, Dr Sebbag participates in the development of the company’s\n\naccess to medicines strategy for the Southern Hemisphere. Prior to joining sanofiaventis,\n\nDr. Sebbag worked in Brussels for the European pharmaceutical industry\n\nassociation (EFPIA), creating a communications platform for the pharmaceutical\n\ncompanies operating in Europe. Before that, he was Senior Vice President\n\nforCommunications for the vaccine company, Aventis Pasteur (today known as sanofi\n\npasteur). In addition to his activities within the pharmaceutical industry, Dr. Sebbag\n\nalso teaches public health courses within the Paris hospital system, focusing on\n\ntropical parasitic diseases. Dr. Sebbag is active within the French Red Cross and has\n\nparticipated in numerous health missions in the Southern Hemisphere. Dr. Sebbag is\n\na Medical Doctor with a specialty in tropical parasitic diseases and training in\n\npsychiatry.\n\nBennett Shapiro Partner, PureTech Ventures\n\nBennett M. Shapiro, M.D. is a Partner at PureTech Ventures. Prior to this, he was\n\nExecutive Vice President of Merck Research Laboratories, responsible for all basic,\n\npreclinical and external research activities worldwide. Earlier, he was Professor and\n\nChairman of the Department of Biochemistry at the University of Washington. He is\n\nthe author of over 120 papers on the molecular regulation of cellular behavior and the\n\ncellular activations at fertilization. Shapiro has bachelor’s degree in chemistry from\n\nDickinson College and a doctor’s degree in medicine from Jefferson Medical College.\n\nFollowing an Internship in Medicine at the University of Pennsylvania Hospital, he\n\nwas a Research Associate at the NIH, then a Visiting Scientist at the Institut Pasteur\n\nin Paris, and returned to the NIH as Chief – Section on Cellular Differentiation in the\n\nLaboratory of Biochemistry, prior to joining the University of Washington. He has\n\nserved on many institutional advisory boards and scientific review panels. Shapiro is\n\nChairman of Vascular Biogenics, Ltd., and a Director of Momenta Pharmaceuticals,\n\nCelera, Protein Forest, Satori, and Elixir Pharmaceuticals. He also a Director of DNDi\n\nand Chairman of the Drugs for Neglected Diseases initiative-North America.\n\nMae Shieh Novartis Vaccines Institute for Global Health (NVGH)\n\nMae joined the Novartis Vaccines Institute for Global Health (NVGH) in Siena, Italy, in\n\nJuly 2007 and is responsible for external collaborations, partnerships and licensing.\n\nShe has previous experience in building partnerships between industry and NGOs\n\nand funders from working for 4 years at the Novartis Institute for Tropical Diseases\n\n(NITD) in Singapore, where partnerships with the Wellcome Trust, the Grand\n\nChallenges for Global Health, and the Global Alliance for TB Drug Development were\n\nestablished. Mae came to Novartis in March 2000 after obtaining an MBA from\n\nINSEAD (Fontainebleau, France) and has an engineering degree from Purdue\n\nUniversity in the USA. She is currently working on a Masters in International Health\n\n(MIH) degree from the Swiss Tropical Institute and the TropEd Network on a part-time\n\nbasis.\n\nBilly Tauzin President and Chief Executive Officer, Pharmaceutical Research and Manufacturers of America (PhRMA)\n\nBilly Tauzin became president and chief executive officer of the Pharmaceutical\n\nResearch and Manufacturers of America (PhRMA) in 2005, after long career in public\n\nservice career, including 13 terms representing the 3rd Congressional District of\n\nLouisiana. First elected to the House in 1980 as a Democrat, he switched parties in\n\n1995. In 1998, he joined with House Majority Leader Dick Armey to propose a\n\nrevamping of the tax code. He held several leadership positions in Congress,\n\nincluding chairmanship of a Merchant Marine Subcommittee, and was Deputy\n\nMajority Whip. More recently, he served as Chairman of the influential House\n\nCommittee on Energy and Commerce, which has jurisdiction over all interstate and\n\nforeign commerce, including energy, telecommunications, health care, biomedical\n\nresearch, consumer protection, the environment and travel and tourism. In this\n\ncapacity, he helped President George W. Bush win passage of a Medicare\n\nprescription drug bill. He was also the original author of the Securities Litigation\n\nReform Act and the Cable Act – the only bills over the past decade to become law\n\ndespite a Presidential veto. Billy Tauzin began his public service career in the\n\nLouisiana State Legislature where he served as Chairman of the House Natural\n\nResources Committee and Chief Administration Floor Leader. Billy Tauzin received a\n\nBachelor of Arts Degree from Nicholls State University in 1964 and a Law Degree\n\nfrom Louisiana State University in 1967.\n\nRussell Williams Head, Canadian pharmaceutical industry association Rx&D\n\nMr. Williams became head of the Canadian pharmaceutical industry association\n\nRx&D after a successful career in provincial politics and community service. For\n\nfifteen years, Mr. Williams represented the Montreal riding of Nelligan in the National\n\nAssembly of Quebec. As a Liberal MNA, he led numerous public policy debates on\n\nissues such as the role of government in research and development (R&D),\n\ncompensation for victims of contaminated blood, linguistic policy, access to services\n\nfor handicapped people, pre-hospital emergency services, and gambling. He is an\n\nadvocate for individual rights, and government services focused on the needs of its\n\ncitizens. During his tenure as parliamentary assistant to two Ministers of Health and\n\nSocial Services, Mr. Williams developed strategies for a more efficient and integrated\n\nhealth care system. In addition, he spearheaded the development of an R&D policy\n\nfor the pharmaceutical sector. Prior to and during his political career, Mr. Williams\n\nplayed a key role in numerous non-profit and community-based initiatives in areas\n\nranging from palliative care to human rights.\n\nWeibo Zhang Director, State Intellectual Property Office of the People’s Republic of China\n\nMr. Zhang is Director of the Pharmaceutical Division of the Pharmaceutical & Biologic\n\nInvention Examination Department of patent office of the State Intellectual Property\n\nOffice of the People’s Republic of China. After he graduated from Beijing University\n\nof Traditional Medicine with a bachelor’s degree in medicine in 1991, he began to\n\nwork as a patent examiner at SIPO. In 2004, he obtained an LL.M from John\n\nMarshall Law School and is now studying in Peking University for an MPA. He has\n\npublished numerous articles relating to IPR protection in the pharmaceutical field. He\n\nis part of the PRC’s National Intellectual Property Strategy research group."
    }
}